This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Dupixent
  • /
  • Dupilumab in Eosinophilic Gastritis
Clinical trial

Dupilumab in Eosinophilic Gastritis

Read time: 1 mins
Last updated:21st Apr 2023
Status: Recruiting
Identifier: NCT03678545
Dupilumab in Eosinophilic Gastritis

Brief Summary:

40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks. Study subjects who complete the 12-week treatment phase, may continue into an open label extension study, where dupilumab will be administered every two weeks for a total of 24 weeks.

Detailed Description:
This is a phase 2, multi-center, randomized, double-blind, placebo-controlled trial testing the efficacy of dupilumab vs. placebo in EG. Qualifying subjects will be randomized 1:1 to either study drug (dupilumab) or placebo, and will receive 600 mg once followed by 300 mg doses every two weeks of study treatment for a total of 6 injections. After the 6th injection subjects may continue into an open-label treatment phase in which dupilumab will be administered every two weeks for a total of 24 weeks.

Approximately 14 sites associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) will take part in the study.

The primary objective of this study is to assess the efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to reduce eosinophilic inflammation in the gastrointestinal tract of patients with EG.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are assigned to either drug or placebo, followed by an open label extension
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Actual Study Start Date: May 15, 2021
Estimated Primary Completion Date: October 1, 2023
Estimated Study Completion Date: April 1, 2024

- Active Comparator: Dupilumab
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Estimated enrolment 40
Actual Study start date 15 May 2021
Estimated Study Completion Date 01 April 2024

View full details